StrideBio, Inc.

BridgeBio Pharma, Inc. employs a business model of acquiring rights to or partnering with academic and institutional research in monogenic diseases and genetic cancer indications, often forming singl

Cash is flooding into biopharmaceuticals, but regenerative medicine companies in particular have raked in large sums of cash – in part, because of the high upfront investment in manufacturing, but als

UCB S.A. ’s ambitions to be a key player in gene therapy have advanced with the acquisition of fellow Belgian firm Handl Therapeutics and an R&D collaboration with Lacerta Therapeutics Inc of the

Investors in Newron Pharmaceuticals SPA have reacted nervously to the news that US regulators have called in the Italian drugmaker for discussions about its Rett syndrome drug, sarizotan, before piv